lupus.bmj14h
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
lupus.bmj20h
Association of race and ethnicity with mortality in adults with SLE: a systematic literature review and meta-analysis
Objectives Ethnicity and health outcomes are intrinsically interrelated, although mechanisms are complex. SLE is a disease ...
Renal & Urology News1d
Gamma Delta CAR T-Cell Therapy Fast Tracked for SLE With Extrarenal Involvement
The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.
emjreviews.com5d
Lupus nephritis drug delivers promising results, says Roche
Obinutuzumab could reshape the treatment of lupus nephritis, a life-threatening complication of lupus that has long lacked ...
Pharmaceutical Technology5d
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
PharmiWeb5d
New England Journal of Medicine publishes new data…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...